Skip to main
BLTE
BLTE logo

BLTE Stock Forecast & Price Target

BLTE Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Belite Bio Inc has received positive interim Phase 3 results for its lead asset tinlarebant, which may heighten interest in potential treatment options for both Stargardt disease and dry age-related macular degeneration (AMD). The company is expected to drive share appreciation in the upcoming 12-18 months, backed by updates from its ongoing Phase 3 programs and an increase in sample size for the PHOENIX trial. Additionally, tinlarebant's recognition through multiple designations, including fast track and orphan drug status, underscores its promising clinical profile and potential market value, leading to an updated DCF-based equity value estimate significantly higher than previous forecasts.

Bears say

Belite Bio Inc has consistently reported operating losses since its inception, with a net loss of $36.1 million in 2024, leading to concerns about the company's potential for profitability in the near future. The dependence on reimbursement policies, which may be jeopardized by economic factors such as austerity measures and consumer financial health, adds additional risk to the firm's revenue projections. Moreover, the uncertainty surrounding regulatory outcomes and reimbursement frameworks further heightens the volatility and risk associated with Belite Bio's stock.

BLTE has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Belite Bio Inc (BLTE) Forecast

Analysts have given BLTE a Strong Buy based on their latest research and market trends.

According to 5 analysts, BLTE has a Strong Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Belite Bio Inc (BLTE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.